IT·SCIENCE

S. Korea's KIT to unveil 45 promising biotech, toxicology technologies

by
Koo Bon-hyuk
Published : Nov. 16, 2026 - 09:13:37
    • Copy Completed!

View Korean Original

Human liver, kidney organoids and AI-based pathology analysis among highlights

A view of the Korea Institute of Toxicology. [Herald DB]
A view of the Korea Institute of Toxicology. [Herald DB]

Forty-five promising technologies in biotech and toxicology developed by South Korean researchers — ranging from lab-grown artificial organs that can replace animal testing to AI-powered pathology analysis — will be presented to industry.

The Korea Institute of Toxicology (KIT) announced Monday that it will hold a "2026 Commercialization Technology Showcase" on Tuesday at the Textile Center in Gangnam-gu, Seoul.

The event is designed to introduce KIT's research achievements in toxicology and biotech to companies and identify concrete commercialization opportunities, including technology transfers and joint research projects. One-on-one technology consultations between researchers and corporate representatives will also be held.

The 45 technologies span five categories: 13 drug candidates and active compounds, 19 new approach methodologies (NAMs) as alternatives to animal testing, three toxicity assessment methods and devices, five biomarkers, diagnostic kits and sensors, and five biomaterials and functional materials.

Particularly notable are advanced technologies that can evaluate the efficacy and toxicity of drug candidates while reducing reliance on animal testing.

Among the highlights are a next-generation cartilage evaluation model that mimics human cartilage tissue to assess drug efficacy and toxicity, along with human-derived liver and kidney organoid technologies.

Organoids are three-dimensional cell models that replicate the structure and function of human organs and can be used to evaluate drug responses and toxicity during the drug development process.

Data from an AI-based pathology analysis model and related software will also be released. Additional research outputs applicable to the biotech industry — including natural product-based materials for disease management — are also set to be introduced.

KIT said it aims to use the showcase to identify companies' technology needs and expand the application of its research in industrial settings.

In addition, KIT will run a "technology sharing" initiative through year-end, transferring unused patents it holds to companies at low or no cost. Eligible patents will be listed on the KIT website and a newly built technology transfer platform.

"We will work to ensure that the core technologies developed at our institute translate into outcomes that the nation, the public and industry can tangibly benefit from," KIT Director Heo Jeong-du said.


nbgkoo@heraldcorp.com
This content was produced with the assistance of AI translation services.

MOST READ